S
Simon Chowdhury
Researcher at St Thomas' Hospital
Publications - 233
Citations - 13378
Simon Chowdhury is an academic researcher from St Thomas' Hospital. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 34, co-authored 208 publications receiving 9526 citations. Previous affiliations of Simon Chowdhury include King's College London & St Bartholomew's Hospital.
Papers
More filters
Journal ArticleDOI
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Tomasz M. Beer,Andrew J. Armstrong,Dana E. Rathkopf,Yohann Loriot,Cora N. Sternberg,Celestia S. Higano,Peter Iversen,Suman Bhattacharya,Joan Carles,Simon Chowdhury,Ian D. Davis,Johann S. de Bono,Christopher P. Evans,Karim Fizazi,Anthony M. Joshua,Choung-Soo Kim,Go Kimura,Paul N. Mainwaring,Harry H. Mansbach,Kurt Miller,Sarah B. Noonberg,Frank Perabo,De Phung,Fred Saad,Howard I. Scher,Mary-Ellen Taplin,Peter Venner,Bertrand Tombal +27 more
TL;DR: Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer.
Journal ArticleDOI
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James,Nicholas D. James,Matthew R. Sydes,Noel W. Clarke,Malcolm David Mason,David P. Dearnaley,Melissa R. Spears,Alastair W. S. Ritchie,Chris Parker,J. Martin Russell,Gerhardt Attard,Johann S. de Bono,William Cross,Robert Jones,George N. Thalmann,Claire Amos,David Matheson,Robin Millman,Mymoona Alzouebi,Sharon Beesley,Alison Birtle,Susannah Brock,Richard Cathomas,Prabir Chakraborti,Simon Chowdhury,Audrey Cook,Tony Elliott,Joanna Gale,Stephanie Gibbs,John Graham,J. Hetherington,Robert Hughes,Robert W. Laing,Fiona McKinna,Duncan McLaren,Joe M. O'Sullivan,Omi Parikh,Clive Peedell,Andrew Protheroe,Angus Robinson,Narayanan Srihari,Rajaguru Srinivasan,John Staffurth,Santhanam Sundar,Shaun Tolan,David Tsang,John Wagstaff,Mahesh K.B. Parmar +47 more
TL;DR: Zoledronic acid showed no evidence of survival improvement and should not be part of standard of care for this population of men, and heterogeneity in treatment effect across prespecified subsets was not found.
Journal ArticleDOI
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas D. James,Johann S. de Bono,Melissa R. Spears,Noel W. Clarke,Malcolm David Mason,David P. Dearnaley,Alastair W. S. Ritchie,Claire Amos,Clare Gilson,Robert Jones,David Matheson,Robin Millman,Gerhardt Attard,Simon Chowdhury,William Cross,Silke Gillessen,Chris Parker,J. Martin Russell,Dominik Berthold,Chris Brawley,Fawzi Adab,San Aung,Alison Birtle,Jo Bowen,Susannah Brock,Prabir Chakraborti,C.L. Ferguson,Joanna Gale,Emma Gray,Mohan Hingorani,Peter Hoskin,Jason F. Lester,Zafar Malik,Fiona McKinna,Neil McPhail,Julian Money-Kyrle,Joe M. O'Sullivan,Omi Parikh,Andrew Protheroe,Angus Robinson,Narayanan Srihari,Carys Thomas,John Wagstaff,James D. Wylie,Anjali Zarkar,Mahesh K.B. Parmar,Matthew R. Sydes +46 more
TL;DR: Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher rates of overall and failure‐free survival than ADT alone.
Journal ArticleDOI
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Chris Parker,Nicholas D. James,Christopher D. Brawley,Noel W. Clarke,Alex Hoyle,Adnan Ali,A.W.S. Ritchie,Gerhardt Attard,Simon Chowdhury,William Cross,David P. Dearnaley,Silke Gillessen,Silke Gillessen,Clare Gilson,Robert Jones,Ruth E Langley,Zafar Malik,Malcolm David Mason,David Matheson,Robin Millman,J. Martin Russell,George N. Thalmann,Claire Amos,Roberto Alonzi,Amit Bahl,Alison Birtle,O.S. Din,Hassan Douis,C. Eswar,Joanna Gale,Melissa Gannon,Sai Jonnada,S. Khaksar,Jason F. Lester,Joe M. O'Sullivan,Omi Parikh,Ian Pedley,Delia Pudney,D. Sheehan,Narayanan Srihari,Anna T.H. Tran,Mahesh K.B. Parmar,Matthew R. Sydes +42 more
TL;DR: Radiotherapy to the prostate did not improve overall survival for unselected patients with newly diagnosed metastatic prostate cancer, and the benefit would be greatest in patients with a low metastatic burden.
Journal ArticleDOI
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Kim N. Chi,Neeraj Agarwal,Anders Bjartell,Byung Ha Chung,Andrea J. Pereira de Santana Gomes,Robert Given,Álvaro Juárez Soto,Axel S. Merseburger,Mustafa Ozguroglu,Hirotsugu Uemura,Dingwei Ye,Kris Deprince,V. Naini,Jinhui Li,Shinta Cheng,Margaret K. Yu,Ke Zhang,Julie S. Larsen,Sharon Anne McCarthy,Simon Chowdhury +19 more
TL;DR: Overall survival and radiographic progression-free survival were significantly longer with the addition of apalutamide to ADT than with placebo plus ADT, and the side-effect profile did not differ substantially between the two groups.